Minims Cyclopentolate
Minims Cyclopentolate Brand names, Minims Cyclopentolate Analogs
Minims Cyclopentolate Brand Names Mixture
- No information avaliable
Minims Cyclopentolate Chemical_Formula
C17H25NO3
Minims Cyclopentolate RX_link
No information avaliable
Minims Cyclopentolate fda sheet
Minims Cyclopentolate msds (material safety sheet)
Minims Cyclopentolate Synthesis Reference
No information avaliable
Minims Cyclopentolate Molecular Weight
291.385 g/mol
Minims Cyclopentolate Melting Point
139 oC (hydrochloride salt)
Minims Cyclopentolate H2O Solubility
No information avaliable
Minims Cyclopentolate State
Solid
Minims Cyclopentolate LogP
3.124
Minims Cyclopentolate Dosage Forms
Ophthalmic solution (eye drops)
Minims Cyclopentolate Indication
Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.
Minims Cyclopentolate Pharmacology
Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises.
Minims Cyclopentolate Absorption
Absorbed following ophthalmic administration.
Minims Cyclopentolate side effects and Toxicity
Oral LD50 in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.
Minims Cyclopentolate Patient Information
No information avaliable
Minims Cyclopentolate Organisms Affected
Humans and other mammals
